Trypanosoma cruzi infection in transfusion medicine

Gómez, Lina Andrea; Gutierrez, Fredy R. S.; Peñuela, Oscar

doi:10.1016/j.htct.2018.12.001

Cited by 16 publications

(31 citation statements)

References 35 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…American trypanosomiasis or Chagas’ disease is caused by the parasite Trypanosoma cruzi ( T. cruzi ) [8,9,10,11]. Currently 6 to 8 million people are infected and more than 100 million are at risk [12]. Chagas’ disease (CD) presents two clinical stages, an acute phase where symptoms are more asymptomatic, and a chronic phase which leads to heart failure or even death [13].…”

Section: Introductionmentioning

confidence: 99%

Trypanocidal Mechanism of Action and in silico Studies of p-Coumaric Acid Derivatives

Lopes

Castillo

Monteiro

et al. 2019

IJMS

View full text Add to dashboard Cite

Trypanosoma species are responsible for chronic and systemic infections in millions of people around the world, compromising life quality, and family and government budgets. This group of diseases is classified as neglected and causes thousands of deaths each year. In the present study, the trypanocidal effect of a set of 12 ester derivatives of the p-coumaric acid was tested. Of the test derivatives, pentyl p-coumarate (7) (5.16 ± 1.28 μM; 61.63 ± 28.59 μM) presented the best respective trypanocidal activities against both epimastigote and trypomastigote forms. Flow cytometry analysis revealed an increase in the percentage of 7-AAD labeled cells, an increase in reactive oxygen species, and a loss of mitochondrial membrane potential; indicating cell death by necrosis. This mechanism was confirmed by scanning electron microscopy, noting the loss of cellular integrity. Molecular docking data indicated that of the chemical compounds tested, compound 7 potentially acts through two mechanisms of action, whether by links with aldo-keto reductases (AKR) or by comprising cruzain (CZ) which is one of the key Trypanosoma cruzi development enzymes. The results indicate that for both enzymes, van der Waals interactions between ligand and receptors favor binding and hydrophobic interactions with the phenolic and aliphatic parts of the ligand. The study demonstrates that p-coumarate derivatives are promising molecules for developing new prototypes with antiprotozoal activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Trypanocidal Mechanism of Action and in silico Studies of p-Coumaric Acid Derivatives

Lopes

Castillo

Monteiro

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Segundo Gomes vários outros países como Estados Unidos, França, Argentina, Espanha, México, Colômbia, Inglaterra, Venezuela e Chile demostraram também preocupação nessa tarefa, visto que a Organização Mundial da Saúde declara que existem quase 20 milhões de pessoas infectadas nas Américas (Gómez, et al, 2019 (Chagas, 1909).…”

Section: Transmissão Transfusional Como Problema De Saúde Públicaunclassified

Tripanossomíase americana e transfusão de sangue: uma perspectiva em áreas endêmicas e não endêmicas na América

Silva¹,

Nascimento²,

Carvalho³

et al. 2020

RSD

View full text Add to dashboard Cite

Este estudo teve como objetivo apresentar um breve histórico da doença e seu potencial risco de transmissão pós-erradicação do vetor em banco de sangue, bem como abordar propostas de monitoramento e prevenção em bancos de sangue para impedir a disseminação da doença. Trata-se de uma revisão narrativa da literatura com manuais, livros, teses, monografias e periódicos científicos publicados em português e inglês, nas bibliotecas abertas e virtuais da BIREME (Biblioteca Regional de Medicina), LILACS (Literatura Latino-Americana em Ciências da Saúde) e SCIELO (Scientific Electronic Library Online) por meio dos descritores: tripanossomíase, doença de Chagas e hemoterapia. Em toda a América Latina, a taxa de incidência da doença de Chagas era de 6,8% na década de 1980 e diminuiu para 1,3% em 2006, o que representa uma mudança significativa no perfil epidemiológico. Tanto no Brasil quanto em outros países, os serviços de hemoterapia vêm adotando novas tecnologias para minimizar a disseminação de agentes infecciosos durante a transfusão.

show abstract

“…The majority of individuals in the acute phase have mild or no symptoms. After the acute phase, infected individuals enter a chronic asymptomatic form of disease during which about 30% of the infected individuals go on to develop clinical symptoms associated with CD (5). T. cruzi infection is more difficult to detect in the chronic phase as the number of parasites in the blood reduces significantly and are undetectable by microscopy (6).…”

Section: Introductionmentioning

confidence: 99%

Complete Inactivation of Blood Borne Pathogen Trypanosoma cruzi in Stored Human Platelet Concentrates and Plasma Treated With 405 nm Violet-Blue Light

et al. 2020

View full text Add to dashboard Cite

The introduction of pathogen reduction technologies (PRTs) to inactivate bacteria, viruses and parasites in donated blood components stored for transfusion adds to the existing arsenal toward reducing the risk of transfusion-transmitted infectious diseases (TTIDs). We have previously demonstrated that 405 nm violet-blue light effectively reduces blood-borne bacteria in stored human plasma and platelet concentrates. In this report, we investigated the microbicidal effect of 405 nm light on one important bloodborne parasite Trypanosoma cruzi that causes Chagas disease in humans. Our results demonstrated that a light irradiance at 15 mWcm−2 for 5 h, equivalent to 270 Jcm−2, effectively inactivated T. cruzi by over 9.0 Log10, in plasma and platelets that were evaluated by a MK2 cell infectivity assay. Giemsa stained T. cruzi infected MK2 cells showed that the light-treated parasites in plasma and platelets were deficient in infecting MK2 cells and did not differentiate further into intracellular amastigotes unlike the untreated parasites. The light-treated and untreated parasite samples were then evaluated for any residual infectivity by injecting the treated parasites into Swiss Webster mice, which did not develop infection even after the animals were immunosuppressed, further demonstrating that the light treatment was completely effective for inactivation of the parasite; the light-treated platelets had similar in vitro metabolic and biochemical indices to that of untreated platelets. Overall, these results provide a proof of concept toward developing 405 nm light treatment as a pathogen reduction technology (PRT) to enhance the safety of stored human plasma and platelet concentrates from bloodborne T. cruzi, which causes Chagas disease.

show abstract

Trypanosoma cruzi infection in transfusion medicine

Cited by 16 publications

References 35 publications

Trypanocidal Mechanism of Action and in silico Studies of p-Coumaric Acid Derivatives

Trypanocidal Mechanism of Action and in silico Studies of p-Coumaric Acid Derivatives

Tripanossomíase americana e transfusão de sangue: uma perspectiva em áreas endêmicas e não endêmicas na América

Complete Inactivation of Blood Borne Pathogen Trypanosoma cruzi in Stored Human Platelet Concentrates and Plasma Treated With 405 nm Violet-Blue Light

Contact Info

Product

Resources

About